Preliminary experience on the use of sucrosomial iron in hemodialysis: focus on safety, hemoglobin maintenance and oxidative stress

Int Urol Nephrol. 2022 May;54(5):1145-1153. doi: 10.1007/s11255-021-02983-8. Epub 2021 Sep 12.

Abstract

Purpose: Iron is usually administered in hemodialysis patients by parenteral route, as oral absorption is poor due to high hepcidin levels. However, administrations of intravenous iron and iron overload are associated with high oxidative stress and systemic inflammation that can affect patient survival. With this study, we evaluated an alternative type of oral iron for the treatment of anemia in hemodialysis patients. The formulation consists in ferric pyrophosphate covered by phospholipids plus sucrose ester of fatty acid matrix, named sucrosomial iron, whose absorption is not influenced by hepcidin.

Methods: Twenty-four (24) patients undergoing chronic hemodialysis switched iron supplementation from intravenous (ferric gluconate 62.5 mg weekly) to oral (sucrosomial iron, 90 mg weekly in 3 administrations of 30 mg) route for 3 months. Classical anemia, iron metabolism, inflammation and nutritional biomarkers were monitored, as well as biomarkers of oxidative stress, such as protein-bound di-tyrosines, protein carbonylation, advanced oxidation protein products and protein thiols.

Results: Over the 3 months, hemoglobin values remained stable, as the values of hematocrit and mean corpuscular volume. In parallel, other anemia parameters dropped, including ferritin, transferrin saturation and serum iron. On the other side, nutritional biomarkers, such as total proteins and transferrin, increased significantly during the time frame. We also observed a significant decrease in white blood cells as well as a non-significant reduction in C-reactive protein and some oxidative stress biomarkers, such as protein carbonyls and di-tyrosines.

Conclusion: Our study demonstrates that a therapy with sucrosomial iron in hemodialysis patients is safe and can maintain stable hemoglobin levels in a three-month period with a possible beneficial effect on oxidative stress parameters. However, the reduction of ferritin and transferrin saturation suggests that a weekly dosage of 90 mg is not sufficient in hemodialysis patients in the long time to maintain hemoglobin.

Keywords: Anemia; Dialysis; Iron supplementation; Oxidative stress; Sucrosomial iron.

MeSH terms

  • Anemia* / etiology
  • Biomarkers / metabolism
  • Erythropoietin*
  • Ferric Compounds
  • Ferritins
  • Hemoglobins / metabolism
  • Hepcidins
  • Humans
  • Inflammation / etiology
  • Iron / metabolism
  • Oxidative Stress
  • Renal Dialysis / adverse effects
  • Transferrin / metabolism

Substances

  • Biomarkers
  • Ferric Compounds
  • Hemoglobins
  • Hepcidins
  • Transferrin
  • sucrosomial iron
  • Erythropoietin
  • Ferritins
  • Iron